Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 May 15;99(10):2538–2544. doi: 10.1172/JCI119438

Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.

G Di Cola 1, M H Cool 1, D Accili 1
PMCID: PMC508095  PMID: 9153298

Abstract

We have investigated the metabolic actions of recombinant human IGF-1 in mice genetically deficient of insulin receptors (IR-/-). After intraperitoneal administration, IGF-1 caused a prompt and sustained decrease of plasma glucose levels in IR-/- mice. Plasma free fatty acid concentrations were unaffected. Interestingly, the effects of IGF-1 were identical in normal mice (IR+/+) and in IR-/- mice. Despite decreased glucose levels, IR-/- mice treated with IGF-1 died within 2-3 d of birth, like sham-treated IR-/- controls. In skeletal muscle, IGF-1 treatment caused phosphorylation of IGF-1 receptors and increased the levels of the phosphatidylinositol-3-kinase p85 subunit detected in antiphosphotyrosine immunoprecipitates, consistent with the possibility that IGF-1 stimulates glucose uptake in a phosphatidylinositol-3-kinase-dependent manner. IGF-1 receptor phosphorylation and coimmunoprecipitation of phosphatidylinositol3-kinase by antiphosphotyrosine antibodies was also observed in liver, and was associated with a decrease in mRNA levels of the key gluconeogenetic enzyme phosphoenolpyruvate carboxykinase. Thus, the effect of IGF-1 on plasma glucose levels may be accounted for by increased peripheral glucose use and by inhibition of hepatic gluconeogenesis. These data indicate that IGF-1 can mimic insulin's effects on glucose metabolism by acting through its own receptor. The failure of IGF-1 to rescue the lethal phenotype due to lack of insulin receptors suggests that IGF-1 receptors cannot effectively mediate all the metabolic actions of insulin receptors.

Full Text

The Full Text of this article is available as a PDF (283.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Accili D., Drago J., Lee E. J., Johnson M. D., Cool M. H., Salvatore P., Asico L. D., José P. A., Taylor S. I., Westphal H. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet. 1996 Jan;12(1):106–109. doi: 10.1038/ng0196-106. [DOI] [PubMed] [Google Scholar]
  2. Accili D. Molecular defects of the insulin receptor gene. Diabetes Metab Rev. 1995 Apr;11(1):47–62. doi: 10.1002/dmr.5610110105. [DOI] [PubMed] [Google Scholar]
  3. Backeljauw P. F., Alves C., Eidson M., Cleveland W., Underwood L. E., Davenport M. L. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res. 1994 Dec;36(6):749–754. doi: 10.1203/00006450-199412000-00012. [DOI] [PubMed] [Google Scholar]
  4. Backer J. M., Myers M. G., Jr, Shoelson S. E., Chin D. J., Sun X. J., Miralpeix M., Hu P., Margolis B., Skolnik E. Y., Schlessinger J. Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992 Sep;11(9):3469–3479. doi: 10.1002/j.1460-2075.1992.tb05426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Backer J. M., Myers M. G., Jr, Sun X. J., Chin D. J., Shoelson S. E., Miralpeix M., White M. F. Association of IRS-1 with the insulin receptor and the phosphatidylinositol 3'-kinase. Formation of binary and ternary signaling complexes in intact cells. J Biol Chem. 1993 Apr 15;268(11):8204–8212. [PubMed] [Google Scholar]
  6. Baker J., Liu J. P., Robertson E. J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993 Oct 8;75(1):73–82. [PubMed] [Google Scholar]
  7. Beale E. G., Chrapkiewicz N. B., Scoble H. A., Metz R. J., Quick D. P., Noble R. L., Donelson J. E., Biemann K., Granner D. K. Rat hepatic cytosolic phosphoenolpyruvate carboxykinase (GTP). Structures of the protein, messenger RNA, and gene. J Biol Chem. 1985 Sep 5;260(19):10748–10760. [PubMed] [Google Scholar]
  8. Bilan P. J., Ramlal T., Klip A. IGF-I mediated recruitment of glucose transporters from intracellular membranes to plasma membranes in L6 muscle cells. Adv Exp Med Biol. 1991;293:273–288. doi: 10.1007/978-1-4684-5949-4_25. [DOI] [PubMed] [Google Scholar]
  9. Bondy C. A., Underwood L. E., Clemmons D. R., Guler H. P., Bach M. A., Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med. 1994 Apr 1;120(7):593–601. doi: 10.7326/0003-4819-120-7-199404010-00011. [DOI] [PubMed] [Google Scholar]
  10. Boulware S. D., Tamborlane W. V., Rennert N. J., Gesundheit N., Sherwin R. S. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 1994 Mar;93(3):1131–1139. doi: 10.1172/JCI117065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Caro J. F., Poulos J., Ittoop O., Pories W. J., Flickinger E. G., Sinha M. K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest. 1988 Apr;81(4):976–981. doi: 10.1172/JCI113451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cheatham B., Kahn C. R. Insulin action and the insulin signaling network. Endocr Rev. 1995 Apr;16(2):117–142. doi: 10.1210/edrv-16-2-117. [DOI] [PubMed] [Google Scholar]
  13. Chou J. Y. Establishment of rat fetal liver lines and characterization of their metabolic and hormonal properties: use of temperature-sensitive SV40 virus. Methods Enzymol. 1985;109:385–396. doi: 10.1016/0076-6879(85)09104-2. [DOI] [PubMed] [Google Scholar]
  14. Dohm G. L., Elton C. W., Raju M. S., Mooney N. D., DiMarchi R., Pories W. J., Flickinger E. G., Atkinson S. M., Jr, Caro J. F. IGF-I--stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes. 1990 Sep;39(9):1028–1032. doi: 10.2337/diab.39.9.1028. [DOI] [PubMed] [Google Scholar]
  15. Frattali A. L., Treadway J. L., Pessin J. E. Insulin/IGF-1 hybrid receptors: implications for the dominant-negative phenotype in syndromes of insulin resistance. J Cell Biochem. 1992 Jan;48(1):43–50. doi: 10.1002/jcb.240480108. [DOI] [PubMed] [Google Scholar]
  16. Froesch E. R., Bianda T., Hussain M. A. Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Diabetes Metab. 1996 Jul;22(4):261–267. [PubMed] [Google Scholar]
  17. Girard J., Ferré P., Pégorier J. P., Duée P. H. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol Rev. 1992 Apr;72(2):507–562. doi: 10.1152/physrev.1992.72.2.507. [DOI] [PubMed] [Google Scholar]
  18. Guler H. P., Zapf J., Froesch E. R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987 Jul 16;317(3):137–140. doi: 10.1056/NEJM198707163170303. [DOI] [PubMed] [Google Scholar]
  19. Hartman M. L., Clayton P. E., Johnson M. L., Celniker A., Perlman A. J., Alberti K. G., Thorner M. O. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest. 1993 Jun;91(6):2453–2462. doi: 10.1172/JCI116480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hussain M. A., Froesch E. R. Treatment of type A insulin resistance with insulin-like growth factor-I. Lancet. 1993 Jun 12;341(8859):1536–1537. doi: 10.1016/0140-6736(93)90674-6. [DOI] [PubMed] [Google Scholar]
  21. Hussain M. A., Schmitz O., Mengel A., Keller A., Christiansen J. S., Zapf J., Froesch E. R. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest. 1993 Nov;92(5):2249–2256. doi: 10.1172/JCI116828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jabri N., Schalch D. S., Schwartz S. L., Fischer J. S., Kipnes M. S., Radnik B. J., Turman N. J., Marcsisin V. S., Guler H. P. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes. 1994 Mar;43(3):369–374. doi: 10.2337/diab.43.3.369. [DOI] [PubMed] [Google Scholar]
  23. Jacob R. J., Sherwin R. S., Greenawalt K., Shulman G. I. Simultaneous insulinlike growth factor I and insulin resistance in obese Zucker rats. Diabetes. 1992 Jun;41(6):691–697. doi: 10.2337/diab.41.6.691. [DOI] [PubMed] [Google Scholar]
  24. Joshi R. L., Lamothe B., Cordonnier N., Mesbah K., Monthioux E., Jami J., Bucchini D. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J. 1996 Apr 1;15(7):1542–1547. [PMC free article] [PubMed] [Google Scholar]
  25. Kuzuya H., Matsuura N., Sakamoto M., Makino H., Sakamoto Y., Kadowaki T., Suzuki Y., Kobayashi M., Akazawa Y., Nomura M. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993 May;42(5):696–705. doi: 10.2337/diab.42.5.696. [DOI] [PubMed] [Google Scholar]
  26. LeRoith D., Werner H., Beitner-Johnson D., Roberts C. T., Jr Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995 Apr;16(2):143–163. doi: 10.1210/edrv-16-2-143. [DOI] [PubMed] [Google Scholar]
  27. Lewitt M. S., Saunders H., Baxter R. C. Regulation of rat insulin-like growth factor-binding protein-1: the effect of insulin-induced hypoglycemia. Endocrinology. 1992 Nov;131(5):2357–2364. doi: 10.1210/endo.131.5.1385101. [DOI] [PubMed] [Google Scholar]
  28. Lund S., Flyvbjerg A., Holman G. D., Larsen F. S., Pedersen O., Schmitz O. Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am J Physiol. 1994 Sep;267(3 Pt 1):E461–E466. doi: 10.1152/ajpendo.1994.267.3.E461. [DOI] [PubMed] [Google Scholar]
  29. Morgan D. O., Jarnagin K., Roth R. A. Purification and characterization of the receptor for insulin-like growth factor I. Biochemistry. 1986 Sep 23;25(19):5560–5564. doi: 10.1021/bi00367a032. [DOI] [PubMed] [Google Scholar]
  30. Morrow L. A., O'Brien M. B., Moller D. E., Flier J. S., Moses A. C. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab. 1994 Jul;79(1):205–210. doi: 10.1210/jcem.79.1.8027228. [DOI] [PubMed] [Google Scholar]
  31. Moses A. C., Young S. C., Morrow L. A., O'Brien M., Clemmons D. R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996 Jan;45(1):91–100. doi: 10.2337/diab.45.1.91. [DOI] [PubMed] [Google Scholar]
  32. Murphy L. J., Seneviratne C., Ballejo G., Croze F., Kennedy T. G. Identification and characterization of a rat decidual insulin-like growth factor-binding protein complementary DNA. Mol Endocrinol. 1990 Feb;4(2):329–336. doi: 10.1210/mend-4-2-329. [DOI] [PubMed] [Google Scholar]
  33. Myers M. G., Jr, Backer J. M., Sun X. J., Shoelson S., Hu P., Schlessinger J., Yoakim M., Schaffhausen B., White M. F. IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10350–10354. doi: 10.1073/pnas.89.21.10350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Myers M. G., Jr, Grammer T. C., Wang L. M., Sun X. J., Pierce J. H., Blenis J., White M. F. Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem. 1994 Nov 18;269(46):28783–28789. [PubMed] [Google Scholar]
  35. Myers M. G., Jr, Sun X. J., Cheatham B., Jachna B. R., Glasheen E. M., Backer J. M., White M. F. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology. 1993 Apr;132(4):1421–1430. doi: 10.1210/endo.132.4.8384986. [DOI] [PubMed] [Google Scholar]
  36. Okada T., Kawano Y., Sakakibara T., Hazeki O., Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem. 1994 Feb 4;269(5):3568–3573. [PubMed] [Google Scholar]
  37. Ooi G. T., Tseng L. Y., Tran M. Q., Rechler M. M. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol. 1992 Dec;6(12):2219–2228. doi: 10.1210/mend.6.12.1283442. [DOI] [PubMed] [Google Scholar]
  38. Pagliassotti M. J., Holste L. C., Moore M. C., Neal D. W., Cherrington A. D. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest. 1996 Jan 1;97(1):81–91. doi: 10.1172/JCI118410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pegorier J. P., Prip-Buus C., Duee P. H., Girard J. Hormonal control of fatty acid oxidation during the neonatal period. Diabete Metab. 1992;18(1 Pt 2):156–160. [PubMed] [Google Scholar]
  40. Pessin J. E. Molecular properties of insulin/IGF-1 hybrid receptors. 4th International Symposium on Insulin, IGFs and their Receptors. Adv Exp Med Biol. 1993;343:133–144. doi: 10.1007/978-1-4615-2988-0_14. [DOI] [PubMed] [Google Scholar]
  41. Poggi C., Le Marchand-Brustel Y., Zapf J., Froesch E. R., Freychet P. Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology. 1979 Sep;105(3):723–730. doi: 10.1210/endo-105-3-723. [DOI] [PubMed] [Google Scholar]
  42. Prip-Buus C., Thumelin S., Chatelain F., Pegorier J. P., Girard J. Hormonal and nutritional control of liver fatty acid oxidation and ketogenesis during development. Biochem Soc Trans. 1995 Aug;23(3):500–506. doi: 10.1042/bst0230500. [DOI] [PubMed] [Google Scholar]
  43. Quin J. D., Fisher B. M., Paterson K. R., Inoue A., Beastall G. H., MacCuish A. C. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med. 1990 Nov 15;323(20):1425–1426. doi: 10.1056/NEJM199011153232016. [DOI] [PubMed] [Google Scholar]
  44. Soos M. A., Field C. E., Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 1993 Mar 1;290(Pt 2):419–426. doi: 10.1042/bj2900419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sun X. J., Rothenberg P., Kahn C. R., Backer J. M., Araki E., Wilden P. A., Cahill D. A., Goldstein B. J., White M. F. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature. 1991 Jul 4;352(6330):73–77. doi: 10.1038/352073a0. [DOI] [PubMed] [Google Scholar]
  46. Takahashi Y., Kadowaki H., Momomura K., Fukushima Y., Orban T., Okai T., Taketani Y., Akanuma Y., Yazaki Y., Kadowaki T. A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. Diabetologia. 1997 Apr;40(4):412–420. doi: 10.1007/s001250050695. [DOI] [PubMed] [Google Scholar]
  47. Taylor S. I. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 1992 Nov;41(11):1473–1490. doi: 10.2337/diab.41.11.1473. [DOI] [PubMed] [Google Scholar]
  48. Treadway J. L., Morrison B. D., Soos M. A., Siddle K., Olefsky J., Ullrich A., McClain D. A., Pessin J. E. Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):214–218. doi: 10.1073/pnas.88.1.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wada J., Liu Z. Z., Alvares K., Kumar A., Wallner E., Makino H., Kanwar Y. S. Cloning of cDNA for the alpha subunit of mouse insulin-like growth factor I receptor and the role of the receptor in metanephric development. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10360–10364. doi: 10.1073/pnas.90.21.10360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. White M. F. The IRS-1 signaling system. Curr Opin Genet Dev. 1994 Feb;4(1):47–54. doi: 10.1016/0959-437x(94)90090-6. [DOI] [PubMed] [Google Scholar]
  51. Yu K. T., Czech M. P. The type I insulin-like growth factor receptor mediates the rapid effects of multiplication-stimulating activity on membrane transport systems in rat soleus muscle. J Biol Chem. 1984 Mar 10;259(5):3090–3095. [PubMed] [Google Scholar]
  52. Zenobi P. D., Glatz Y., Keller A., Graf S., Jaeggi-Groisman S. E., Riesen W. F., Schoenle E. J., Froesch E. R. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol. 1994 Sep;131(3):251–257. doi: 10.1530/eje.0.1310251. [DOI] [PubMed] [Google Scholar]
  53. Zenobi P. D., Jaeggi-Groisman S. E., Riesen W. F., Røder M. E., Froesch E. R. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest. 1992 Dec;90(6):2234–2241. doi: 10.1172/JCI116109. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES